Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.